Abstract
Aims: Patients with heart failure and preserved ejection fraction (HFpEF) are characterized by functional impairment and an abnormal haemodynamic response to exercise. The six-minute walk test (6MWT) serves as a standardized test for functional capacity quantification in heart failure patients, and is associated with cardiovascular outcomes. However, as the association between 6MWT and haemodynamic parameters during rest and exercise in HFpEF patients is unknown, we sought to elucidate this relationship. Methods and results: Overall, 64 patients enrolled in the REDUCE LAP-HF trial completed a 6MWT at baseline. Univariate and multivariable linear regression models were used to assess the associations between 6MWT and measured or derived haemodynamic variables at baseline, during light/moderate exercise (20 W), and at peak supine exercise. The average 6MWT distance was 318 ± 106 m. At rest, in a multivariable model, only pulmonary capillary wedge pressure (PCWP) was significantly associated with 6MWT [coefficient: –5.4, 95% confidence interval (CI) –10.4, –0.5, P = 0.033]. During light/moderate exercise, mean pulmonary artery pressure was associated with 6MWT in a multivariable model (coefficient: –3.5, 95% CI –6.8, –0.3, P = 0.033). During peak exercise, central venous pressure, cardiac index (CI), and PCWP/CI correlated with 6MWT; however, workload corrected PCWP was the only variable independently associated with 6MWT (coefficient: –0.8, 95% CI –1.3, –0.4, P < 0.001). The variance in 6MWT was modestly explained by measured or derived haemodynamic variables at rest or at any stage of exercise (r2 = 7–17%). Conclusion: Workload corrected PCWP correlated best with 6MWT performance in HFpEF patients. Baseline haemodynamic variables were modestly correlated with 6MWT, suggesting that 6MWT performance in HFpEF patients may be significantly influenced by extra-cardiac factors.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Journal of Heart Failure |
| Vol/bind | 20 |
| Udgave nummer | 4 |
| Sider (fra-til) | 715-722 |
| Antal sider | 8 |
| ISSN | 1388-9842 |
| DOI | |
| Status | Udgivet - 2018 |
Finansiering
1Department of Cardiology, Rigshospitalet, Copenhagen, Denmark; 2Baker IDI Heart and Diabetes Research Institute, Melbourne, Australia; 3Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA; 4Cardiovascular Research Foundation, Orangeburg, NY, USA; 5Department of Internal Medicine, School of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA; 6DC Devices, Boston, MA, USA; 7National Heart Centre Singapore, Singapore, and Duke-National University of Singapore, Singapore; 8Department of Heart Diseases, Medical University and Centre for Heart Diseases, Military Hospital, Wrocław, Poland; and 9Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA The REDUCE HF-LAP study was financed by Corvia Medical, Inc. Conflict of interest: E.W. has none to declare. D.K. receives unrestricted research grants and is an unpaid members of the Corvia Medical Scientific Advisory Group. B.A.B. receives research funding from the NHLBI (RO1 HL128526 and U10 HL110262), Mast Therapeutics, Medtronic, GlaxoSmithKline, and Teva; has consulted and served on advisory boards for Actelion, Amgen, AstraZeneca, Merck and MyoKardia. D.B.: Hemodynamic Core Laboratory for Corvia Medical; Founder PVLoops, LLC. D.W.K. received consulting fees from Corvia Medical, Medtronic, Bayer, Merck, Relypsa, and Abbvie, and research funding from Novartis. J.K. is employee of Corvia Medical, Inc. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has consulted for Bayer, Novartis, Takeda, Merck, Astra Zeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingel-heim and Abbott Diagnostics; has been compensated as a member of the CEC for REDUCE LAP-HF. P.P. receives unrestricted research grants and is an unpaid member of the Corvia Medical Scientific Advisory Group. S.J.S. received research funding from Actelion, AstraZeneca, Corvia, and Novarits, and consulting fees from Actelion, AstraZeneca, Bayer, Ironwood, Merck, Novartis, and Sanofi. F.G. receives unrestricted research grants and is an unpaid member of the Corvia Medical Scientific Advisory Group.
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS